BRNS Valuation

Barinthus Biotherapeutics PLC

Add to Watchlist

Advanced Chart

0.685

-0.002(-0.290%)

Overview
Forecast
Valuation

BRNS Relative Valuation

BRNS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BRNS is overvalued; if below, it's undervalued.

Historical Valuation

Barinthus Biotherapeutics PLC (BRNS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 33.54. The fair price of Barinthus Biotherapeutics PLC (BRNS) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：0.69

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.21

P/B

Median3y

0.46

Median5y

0.58

-103.72

FCF Yield

Median3y

-56.51

Median5y

-44.76

Competitors Valuation Multiple

The average P/S ratio for BRNS's competitors is 0.05, providing a benchmark for relative valuation. Barinthus Biotherapeutics PLC Corp (BRNS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

BRNS.O

Barinthus Biotherapeutics PLC

Loss

Average P/S: 0.05

27.63M